Establishment and clinical application of time-resolved immunofluorescence assay of lipoprotein-associated phospholipase A2

• Published in: Analytical biochemistry Vol. 648; p. 114674
• Main Authors: Chen, Xindong, Zhou, Kewen, Xiang, Zhongyi, Zhou, Xiumei, Wang, Yigang, Hong, Jianfeng, Huang, Biao, Qin, Yuan, Fang, Hongming
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.07.2022
• Subjects: Breast cancer; Dyslipidemia; Lipoprotein-associated phospholipase A2; Time-resolved fluorescence immunoassay; Time-resolved fluorescence immunoassay; Lipoprotein-associated phospholipase A2; Breast cancer; Dyslipidemia
• ISSN: 0003-2697; 1096-0309
• DOI: 10.1016/j.ab.2022.114674

This study aimed to establish a highly sensitive time-resolved fluorescence immunoassay (TRFIA) for the detection of serum lipoprotein-associated phospholipase A2 (Lp-PLA2) and evaluate the clinical application value of Lp-PLA2 in patients with breast cancer. The level of Lp-PLA2 was detected using the double-antibody sandwich method. First, the Lp-PLA2-TRFIA method was established, and the method was evaluated on the basis of linearity, sensitivity, precision, specificity, and recovery rate. Then, the fluorescence counts in serum of healthy subjects and patients with breast cancer were detected by Lp-PLA2-TRFIA, and the levels of Lp-PLA2 were calculated using a standard curve. Lp-PLA2-TRFIA had a wide linear range (43.48–2000 ng/mL). The intra-assay precisions of Lp-PLA2-TRFIA ranged from 2.66% to 4.84% (<10%), and the inter-assay precisions were between 5.39% and 6.95% (<15%). No cross-reaction was observed among Lp-PLA2, Tumor-associated trypsinogen-2, and T-cell immunoglobulin mucin 3. In addition, the recovery rates were between 90% and 100%. The serum Lp-PLA2 levels of patients with breast cancer were significantly higher than those of healthy subjects. We successfully established a highly sensitive Lp-PLA2-TRFIA method, and found serum Lp-PLA2 may be associated with dyslipidemia in breast cancer and could be used for auxiliary diagnose. [Display omitted] •We established Lp-PLA2-TRFIA method to detect serum Lp-PLA2 in the human and evaluated this method.•We found the levels of serum Lp-PLA2 were higher in patients with breast cancer than healthy subjects.•We found that patients with advanced breast cancer had sightly higher Lp-PLA2 levels than those with early breast cancer.•We used ROC curves to distinguish between patients with breast cancer and healthy subjects and found the AUC value was 0.904.